Product logins

Find logins to all Clarivate products below.


Retatrutide

Learn how retatrutide is changing the obesity and T2DM landscape.

What is retatrutide and what sets it apart

Retatrutide could be a “first” in the obesity/overweight and type 2 diabetes mellitus (T2DM) space, by using the “triple G” mechanism (GLP-1, glucose-dependent insulinotropic polypeptide [GIP] and glucagon receptors).

Novel therapies such as this aim to solve limitations such as suboptimal real-world adherence by improving therapeutic potency via its mechanism of action. It could help shift the treatment paradigm to better align with patients’ needs.

About retatrutide

  • Company: Eli Lilly and Co
  • Type: Triple GLP-1, GIP and glucagon RA
  • Usage: Once-weekly subcutaneous administration to manage overweight and obesity and T2DM
    Also being evaluated for osteoarthritis (OA), low back pain, prevention of cardiovascular disease (CVD), obstructive sleep apnea and worsening of kidney disease in individuals with obesity as well as nonalcoholic fatty liver disease (NAFLD)/metabolic dysfunction-associated steatohepatitis (MASH)
  • When will retatrutide be available?
    Expected launch 2028: European Union (obesity), Japan (T2DM), United Kingdom (obesity), United States (obesity and T2DM)
    Expected launch 2029: European Union (T2DM), United Kingdom (T2DM)

Retatrutide sales and success forecasts

$10bn
expected sales for obesity in the G7 markets in 2031*
43%
probability of success for obesity in the United States
$20.1bn
expected sales for T2DM in the G7 markets in 2031*
74%
probability of success for T2DM in the United States

*Because the obesity and T2DM populations overlap, reported sales are not exclusive to each market.

This drug is my most awaited medicine. It has a very high level of efficacy, which could not have been achieved with GLP-1 or GIP / GLP-1 RA. I hope this drug will be developed for obesity in Japan in the future.

Endocrinologist Japan

Drugs in the 2026 list

Related insights

What GLP-1 drugs mean for medtech What GLP-1 drugs mean for medtech
Blog July 2, 2024
What GLP-1 drugs mean for medtech

Are the powerful weight loss and diabetes treatments a lose-lose for medical technology companies? Not necessarily.

The impact of GLP-1RAs on bariatric surgery The impact of GLP-1RAs on bariatric surgery
Webinar
The impact of GLP-1RAs on bariatric surgery

Glucagon-like peptide-1 (GLP-1) receptor agonists have recently witnessed a meteoric rise in popularity for obesity and weight loss. Studies have shown that GLP-1 receptor agonists can be effective for people with obesity, promoting sustained weight management and potentially reducing the risk of weight-related comorbidities. The initial surge in the adoption of these drugs is anticipated...

chevron_left
chevron_right